2301 related articles for article (PubMed ID: 30147690)
21. Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies.
Keller AL; Reiman LT; Perez de Acha O; Parzych SE; Forsberg PA; Kim PS; Bisht K; Wang H; van de Velde H; Sherbenou DW
Cancer Res Commun; 2024 Mar; 4(3):757-764. PubMed ID: 38421887
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma.
Rujirachaivej P; Siriboonpiputtana T; Luangwattananun P; Yuti P; Wutti-In Y; Choomee K; Sujjitjoon J; Chareonsirisuthigul T; Rerkamnuaychoke B; Junking M; Yenchitsomanus PT
Clin Exp Med; 2024 Apr; 24(1):90. PubMed ID: 38683232
[TBL] [Abstract][Full Text] [Related]
23. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
[TBL] [Abstract][Full Text] [Related]
24. Integrating Immune Therapies for the Treatment of Multiple Myeloma.
Mikkilineni L; Sidana S
J Natl Compr Canc Netw; 2023 Dec; 21(12):1303-1311. PubMed ID: 38081142
[TBL] [Abstract][Full Text] [Related]
25. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7
Gogishvili T; Danhof S; Prommersberger S; Rydzek J; Schreder M; Brede C; Einsele H; Hudecek M
Blood; 2017 Dec; 130(26):2838-2847. PubMed ID: 29089311
[TBL] [Abstract][Full Text] [Related]
26. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis.
Gagelmann N; Ayuk F; Atanackovic D; Kröger N
Eur J Haematol; 2020 Apr; 104(4):318-327. PubMed ID: 31883150
[TBL] [Abstract][Full Text] [Related]
27. Novel targets for the treatment of relapsing multiple myeloma.
Giuliani N; Accardi F; Marchica V; Dalla Palma B; Storti P; Toscani D; Vicario E; Malavasi F
Expert Rev Hematol; 2019 Jul; 12(7):481-496. PubMed ID: 31125526
[No Abstract] [Full Text] [Related]
28. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
29. Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting.
Guo R; Lu W; Zhang Y; Cao X; Jin X; Zhao M
Front Immunol; 2022; 13():839097. PubMed ID: 35320942
[TBL] [Abstract][Full Text] [Related]
30. BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them.
Rees MJ; Kumar S
Leuk Lymphoma; 2024 Mar; 65(3):287-300. PubMed ID: 38354090
[TBL] [Abstract][Full Text] [Related]
31. Cell-based immunotherapy approaches for multiple myeloma.
Kriegsmann K; Kriegsmann M; Cremer M; Schmitt M; Dreger P; Goldschmidt H; Müller-Tidow C; Hundemer M
Br J Cancer; 2019 Jan; 120(1):38-44. PubMed ID: 30518815
[TBL] [Abstract][Full Text] [Related]
32. BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma.
Cho SF; Lin L; Xing L; Li Y; Yu T; Anderson KC; Tai YT
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32516895
[TBL] [Abstract][Full Text] [Related]
33. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.
Cohen AD
Am Soc Clin Oncol Educ Book; 2018 May; 38():e6-e15. PubMed ID: 30231373
[TBL] [Abstract][Full Text] [Related]
34. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy.
Zamagni E; Tacchetti P; Pantani L; Cavo M
Expert Rev Hematol; 2018 May; 11(5):423-435. PubMed ID: 29582696
[TBL] [Abstract][Full Text] [Related]
35. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape.
Kazandjian D; Kowalski A; Landgren O
Leuk Lymphoma; 2022 Dec; 63(13):3032-3043. PubMed ID: 36059239
[TBL] [Abstract][Full Text] [Related]
36. Quad-class exposed/refractory myeloma is associated with short survival.
Piron B; Costes-Tertrais D; Gastinne T; Fourmont AM; Dubruille V; Blin N; Moreau P; Touzeau C; Tessoulin B
Br J Haematol; 2024 Jan; 204(1):186-190. PubMed ID: 37833834
[TBL] [Abstract][Full Text] [Related]
37. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.
van de Donk NW; Moreau P; Plesner T; Palumbo A; Gay F; Laubach JP; Malavasi F; Avet-Loiseau H; Mateos MV; Sonneveld P; Lokhorst HM; Richardson PG
Blood; 2016 Feb; 127(6):681-95. PubMed ID: 26631114
[TBL] [Abstract][Full Text] [Related]
38. BCMA-targeting approaches for treatment of multiple myeloma.
Chen Y; Nagarajan C; Tan MS; Martinelli G; Cerchione C
Panminerva Med; 2021 Mar; 63(1):28-36. PubMed ID: 32955181
[TBL] [Abstract][Full Text] [Related]
39. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
Ma T; Shi J; Liu H
Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
[TBL] [Abstract][Full Text] [Related]
40. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
Hipp S; Tai YT; Blanset D; Deegen P; Wahl J; Thomas O; Rattel B; Adam PJ; Anderson KC; Friedrich M
Leukemia; 2017 Aug; 31(8):1743-1751. PubMed ID: 28025583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
